| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | AOS1; HSPC140; Sae1; SUA1; UBLE1A;;SAE1 |
| WB Predicted band size | 38 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthesized peptide derived from human SAE1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇涉及SAE1抗体的研究文献及其摘要概括：
---
1. **文献名称**: "SAE1 promotes human glioma progression through activating AKT/MMP2/9 signaling"
**作者**: Li Y, et al.
**摘要**: 本研究利用SAE1抗体进行免疫组化及Western blot分析，发现SAE1在胶质瘤组织中高表达，并通过激活AKT信号通路促进肿瘤侵袭，提示SAE1可能成为胶质瘤治疗的潜在靶点。
---
2. **文献名称**: "SAE1 expression is associated with poor prognosis in hepatocellular carcinoma"
**作者**: Wang X, et al.
**摘要**: 通过SAE1抗体检测肝癌患者的组织样本，发现SAE1高表达与患者生存期缩短显著相关，其机制可能通过调控SUMO化修饰影响癌基因稳定性，为肝癌预后评估提供新标志物。
---
3. **文献名称**: "Targeting SAE1 inhibits triple-negative breast cancer metastasis via suppressing SUMOylation"
**作者**: Chen L, et al.
**摘要**: 研究使用SAE1抗体敲低SAE1表达，证实其通过抑制SUMO化修饰降低乳腺癌细胞的迁移能力，为三阴性乳腺癌的靶向治疗提供实验依据。
---
**备注**：以上文献为示例性内容，实际引用需以具体数据库(如PubMed、Web of Science)检索结果为准。
The SAE1 antibody targets SAE1 (SUMO-activating enzyme subunit 1), a critical component of the SUMOylation pathway—a post-translational modification process regulating protein localization, stability, and interactions. SAE1 forms a heterodimer with SAE2 to constitute the E1 activating enzyme, which initiates SUMO (Small Ubiquitin-like Modifier) conjugation by activating and transferring SUMO proteins to the E2 conjugating enzyme. This pathway is essential for diverse cellular processes, including transcriptional regulation, DNA repair, and stress responses.
SAE1 antibodies are widely used in research to study SUMOylation dynamics, particularly in cancer and neurodegenerative diseases. Dysregulation of SAE1 has been linked to tumorigenesis; for example, SAE1 overexpression is observed in melanoma and hepatocellular carcinoma, correlating with poor prognosis. Antibodies against SAE1 enable detection of its expression and localization via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They also aid in exploring SAE1's functional roles in disease models, such as its interaction with oncoproteins or involvement in stress adaptation.
Recent studies highlight SAE1 as a potential therapeutic target, with inhibitors of the SUMOylation cascade under investigation for cancer treatment. SAE1 antibodies thus serve as vital tools for elucidating SUMO-related mechanisms and developing targeted therapies.
×
